Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 18,153 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adult ALL Clear all
Recruiting Phase 2 Interventional

Acupuncture for People Experiencing Period Loss Due to Chemotherapy

NCT06915116
View directory record Official record
Conditions
Cancer, Period Problem
Interventions
Acupuncture, No Acupuncture
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 20, 2026, 7:33 PM EDT
Active, not recruiting No phase listed Observational

Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers

NCT02041416
View directory record Official record
Conditions
Cancer, Solid Tumor, Hematologic Malignancy
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 20, 2026, 7:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

NCT02348216
View directory record Official record
Conditions
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
Interventions
Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 20, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

NCT01169714
View directory record Official record
Conditions
Healthy
Interventions
0.1 mg PF-04995274, 1 mg PF-04995274, 10 mg PF-04995274, 15 mg PF-04995274, 1.0 mg PF-04995274
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2011 · Synced Jul 20, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)

NCT00001021
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1IIIB, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
3
States / cities
St Louis, Missouri • Rochester, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 20, 2026, 7:33 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

NCT06630806
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
SAR446523
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
5
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 20, 2026, 7:33 PM EDT
Active, not recruiting Phase 1 Interventional

AutoSTEA for Adults With Functional Dyspepsia

NCT07020416
View directory record Official record
Conditions
Functional Dyspepsia
Interventions
Transcutaneous electrical acustimulation in automatic synchronization with breathing
Device
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Cleveland, Ohio • Parma, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jul 20, 2026, 7:33 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806
View directory record Official record
Conditions
Multiple Myeloma
Interventions
idecabtagene vicleucel, Lenalidomide, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 20, 2026, 7:33 PM EDT
Recruiting No phase listed Observational

HLA Demographics Study in Adults With Type 1 Diabetes

NCT06860516
View directory record Official record
Conditions
Diabetes Mellitus, Type I
Interventions
blood draw or cheek swab
Other
Lead sponsor
GentiBio, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
San Francisco, California • Gainesville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 20, 2026, 7:33 PM EDT
Not listed Not applicable Interventional

Positive Psychology Intervention for Spanish-speaking Hispanic/Latino Adults at Risk for Cardiovascular Disease

NCT03221114
View directory record Official record
Conditions
Uncontrolled Hypertension, Cardiovascular Risk Factor
Interventions
Positive Psychological Intervention
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jul 20, 2026, 7:33 PM EDT
Enrolling by invitation No phase listed Observational

International Registry of Congenital Portosystemic Shunt (IRCPSS)

NCT06041906
View directory record Official record
Conditions
Congenital Portosystemic Shunt, CPSS (Congenital Portosystemic Shunt)
Interventions
Shunt Closure
Procedure
Lead sponsor
Prof. Valérie Mc Lin
Other
Eligibility
1 Day and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 20, 2026, 7:33 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors

NCT03510104
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Neoplasms, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes
Interventions
MRX-2843
Drug
Lead sponsor
Meryx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 20, 2026, 7:33 PM EDT
Completed Phase 2Phase 3 Interventional

Assessment Of Safety Of UK-390,957

NCT00219609
View directory record Official record
Conditions
Ejaculation
Interventions
UK-390,957
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
46
States / cities
Tucson, Arizona • Anaheim, California • Atherton, California + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Jul 20, 2026, 7:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Feasibility of an Internet Intervention for Adults With Spinal Cord Injury to Prevent Pressure Ulcers

NCT01885962
View directory record Official record
Conditions
Spinal Cord Injury, Pressure Ulcers
Interventions
iSHIFTup
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Fishersville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Jul 20, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

NCT03772587
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
M281, Placebo
Drug · Other
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Jul 20, 2026, 7:33 PM EDT
Completed Phase 1 Interventional

Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery

NCT00098579
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor, Recurrent Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
alvocidib, doxorubicin hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Jul 20, 2026, 7:33 PM EDT
Completed Phase 2 Interventional

SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas

NCT00005862
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor, Sarcoma
Interventions
semaxanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jul 20, 2026, 7:33 PM EDT
Recruiting Phase 2 Interventional

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

NCT07244263
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Zasocitinib (Dose A), Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 20, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

NCT05216263
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Hoover, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 20, 2026, 7:33 PM EDT
Completed Phase 1 Interventional

Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

NCT01477021
View directory record Official record
Conditions
Adult Liposarcoma, Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
cyclophosphamide, NY-ESO-1-specific T cells, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Jul 20, 2026, 7:33 PM EDT
Completed Not applicable Interventional

Transdiagnostic Group Therapy (GBAT) for Autistic Adults With Personalized Therapeutics

NCT05512221
View directory record Official record
Conditions
GBAT+Individual, GBAT+Engagement Booster, GBAT+Both
Interventions
GBAT+I, GBAT+E - Phase I, Watchful Waiting and Groups - Phase 2, GBAT+IE
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Jul 20, 2026, 7:33 PM EDT
Terminated Phase 1 Interventional

Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis

NCT05176366
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
ExoFlo
Biological
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Jul 20, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional Results available

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT04579666
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Pegcetacoplan (APL-2), Placebo
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jul 20, 2026, 7:33 PM EDT
Terminated Not applicable Interventional

Transition of Inflammatory Bowel Disease (IBD) Patients From Pediatric to Adult Gastroenterologist (GI)

NCT00360022
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis
Interventions
Joint visits
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
16 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jul 20, 2026, 7:33 PM EDT